Daily News

Circuit Remands Portions Of Controversial Praluent Patent Case

October 12, 2017
A federal circuit judge has reversed a lower court's recent controversial decision to order a biologic cholesterol medication to be taken off the market in response to a patent challenge. While the judge found the decision clearly went against U.S. Supreme Court precedent that requires an injunction not disserve the public interest, ultimately the injunction was pulled because the circuit called for the district court to rehear portions of the underlying patent case. The circuit court vacated and remanded portions...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, news from FDA and much more.